Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 10/20 | 0.52 |
| ▸ | KDR | P35968 | 5/20 | 0.51 |
| ▸ | AURKA | O14965 | 5/20 | 0.50 |
| ▸ | SRC | P12931 | 3/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | LTK | P29376 | 1/20 | 0.50 |
| ▸ | TTK | P33981 | 1/20 | 0.50 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.50 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7209536 | 0.99 | CHEK1 (0.52) | CHEK1EGFRKDRAURKASRC | |
| SCHEMBL7210709 | 0.93 | EGFR (0.53) | CHEK1EGFRKDRAURKASRC | |
| Hydrochloric Acid SCHEMBL7210552 | 0.93 | CHEK1 (0.52) | CHEK1EGFRKDRAURKASRC | |
| Hydrochloric Acid SCHEMBL7206849 | 0.93 | EGFR (0.52) | CHEK1EGFRKDRAURKASRC | |
| SCHEMBL7206973 | 0.90 | CHEK1 (0.54) | CHEK1EGFRKDRAURKASRC | |
| SCHEMBL7205355 | 0.89 | CHEK1 (0.54) | CHEK1EGFRKDRAURKASRC | |
| SCHEMBL7209868 | 0.89 | EGFR (0.55) | CHEK1EGFRKDRAURKASRC | |
| Hydrochloric Acid SCHEMBL7211125 | 0.88 | CHEK1 (0.54) | CHEK1EGFRKDRAURKASRC | |
| SCHEMBL6371867 | 0.88 | CHEK1 (0.54) | CHEK1EGFRKDRAURKASRC | |
| SCHEMBL7205019 | 0.88 | CHEK1 (0.58) | CHEK1EGFRKDRAURKASRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312322-A1 | Use of Oxindole Derivatives in the Treatment of Dementia Related Diseases, Alzheimer's Disease and Conditions Associated with Glycogen Synthase Kinase-3 | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | US | claimed |
| US-20050070559-A1 | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | US | claimed |
| EP-1458394-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | claimed |
| WO-2003055492-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER'S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | claimed |
| US-20090312322-A1 | Use of Oxindole Derivatives in the Treatment of Dementia Related Diseases, Alzheimer's Disease and Conditions Associated with Glycogen Synthase Kinase-3 | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | US | disclosed |
| EP-1458394-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003055492-A1 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER'S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070559-A1 | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | GSK3A, GSK3B, PYGB | CHEK1 881/4885EGFR 2648/4885KDR 3980/4885 |
| US-20090312322-A1 | Use of Oxindole Derivatives in the Treatment of Dementia Related Diseases, Alzheimer's Disease and Conditions Associated with Glycogen Synthase Kinase-3 | GSK3A, GSK3B, PSEN1 | CHEK1 1014/4885EGFR 2302/4885KDR 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.